Kymera Therapeutics (KYMR) Other Non Operating Income (2019 - 2026)

Kymera Therapeutics (KYMR) has reported Other Non Operating Income for 8 consecutive years, with $15.0 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Other Non Operating Income rose 69.37% year-over-year to $15.0 million; the TTM figure through Mar 2026 stood at $44.2 million (up 18.31% YoY), while the FY2025 annual figure was $38.0 million, up 0.72% from the prior year.
• Other Non Operating Income advanced to $15.0 million in Q1 2026 per KYMR's latest filing, from $10.9 million in the prior quarter.
• Across five years, Other Non Operating Income topped out at $15.0 million in Q1 2026 and bottomed at $249000.0 in Q1 2022.
• Historically, Other Non Operating Income has averaged $6.8 million across 5 years, with a median of $7.9 million in 2025.
• Annual changes were most pronounced in 2022 — Other Non Operating Income jumped 3318.18% — and 2025, when it declined 10.38%.
• Kymera Therapeutics' Other Non Operating Income stood at $3.6 million in 2022, then soared by 40.9% to $5.1 million in 2023, then surged by 94.61% to $10.0 million in 2024, then climbed by 9.12% to $10.9 million in 2025, then surged by 37.25% to $15.0 million in 2026.
• Business Quant data shows KYMR's Other Non Operating Income at $15.0 million in Q1 2026, $10.9 million in Q4 2025, and $10.3 million in Q3 2025.